I. de Juan

发表

The deletion of exons 3–5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families

I. Chirivella, P. Bolufer, E. Barragán, 2013, Familial Cancer.

Hereditary Risk Assessment for BRCA Breast and/or Ovarian Cancer

I. Chirivella, A. Lluch, P. Eroles, 2022, Journal of Cancer Science and Clinical Therapeutics.

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH)

J. Cigudosa, F. Rojo, A. Osorio, 2019, Virchows Archiv.

Novel real-time polymerase chain reaction assay for simultaneous detection of recurrent fusion genes in acute myeloid leukemia.

P. Bolufer, E. Barragán, J. Cervera, 2013, The Journal of molecular diagnostics : JMD.

Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital

E. Barragán, J. Aparicio, B. Laíz, 2019, Cancers.

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study

J. Benítez, I. Chirivella, D. Salas, 2015, Familial Cancer.

Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer.

Pascual Bolufer, Cristina Alenda, I. Chirivella, 2015, American journal of cancer research.

The deletion of exons 3–5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families

I. Chirivella, P. Bolufer, E. Barragán, 2013, Familial Cancer.

Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)

I. Chirivella, D. Salas, J. López-Guerrero, 2019, Hereditary cancer in clinical practice.

Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia

P. Bolufer, E. Barragán, J. Cervera, 2016, Leukemia & lymphoma.

Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients.

P. Bolufer, E. Barragán, J. Cervera, 2013, Leukemia research.

Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine.

I. Chirivella, D. Salas, P. Bolufer, 2015, American journal of cancer research.

Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics.

E. Barragán, J. Cervera, M. Sanz, 2019, The Journal of molecular diagnostics : JMD.

Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia

E. Barragán, E. Such, S. Palanca, 2023, International journal of molecular sciences.